5/7/2013

Fellows at the U.K.'s Academy of Medical Sciences will advise investors at Park Vale Capital's F2 Bioscience IV fund, which will invest in drugs and medical devices in late-stage clinical trials. The academy will receive an annual retainer and a portion of the profits.

Related Summaries